Investors
A proven track record of value creation
Our diversified business model allows us to respond to opportunities, while delivering for our stakeholders.
Together we’re building a leading global pharmaceutical business
By putting better health within reach of patients every day through investment, innovation and diversification, we’re enhancing our portfolio responsibly and creating strong shareholder returns.
H1 2025 Interim Results
Watch Riad Mishlawi, CEO
Latest stories
Featured
Hikma delivers a solid H1 performance and re-affirms expectations for strong growth in the second half
Press Release, Financial Results
07 August 2025
- European Injectables growth: a Q&A with Nassim Rahmani, Associate VP, Commercial Europe & Canada Insight, Corporate 08 December 2025 European Injectables growth: a Q&A with Nassim Rahmani, Associate VP, Commercial Europe & Canada
- Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US Press Release, Product 08 December 2025 Hikma launches TYZAVAN™ (vancomycin injection, USP) in the US
- Inspiring women of Hikma - Meet Susana Pereira Sr. Director Quality Systems & Validation – EU & MENA Injectables Story, Leadership 24 November 2025 Inspiring women of Hikma - Meet Susana Pereira Sr. Director Quality Systems & Validation – EU & MENA Injectables
- Hikma celebrates 20 years on the London Stock Exchange Story, Corporate 20 November 2025 Hikma celebrates 20 years on the London Stock Exchange
